Published in final edited form as:

Muscle Nerve. 2012 January ; 45(1): 55–59. doi:10.1002/mus.22232.

Transforming Growth Factor-beta Induces Skeletal Muscle Atrophy and Fibrosis Through the Induction of Atrogin-1 and Scleraxis

Christopher L Mendias, PhD¹, Jonathan P Gumucio, BS¹, Max E Davis¹, Caleb W Bromley¹, Carol S Davis, BS², and Susan V Brooks, PhD²

¹Department of Orthopaedic Surgery, University of Michigan, 109 Zina Pitcher Place, BSRB 2019, Ann Arbor, MI 48109

²Department of Molecular and Integrative Physiology, University of Michigan, 109 Zina Pitcher Place, BSRB 2029, Ann Arbor, MI 48109

Abstract

Introduction—Transforming growth factor-beta (TGF- β) is a well known regulator of fibrosis and inflammation in many tissues. During embryonic development, TGF- β signaling induces the expression of the transcription factor scleraxis which promotes fibroblast proliferation and collagen synthesis in tendons. In skeletal muscle, TGF- β has been shown to induce atrophy and fibrosis, but the effect of TGF- β on muscle contractility and the expression of scleraxis and atrogin-1, an important regulator of muscle atrophy, were not known.

Methods—We treated muscles from mice with TGF- β and measured force production, and scleraxis, procollagen I α 2 and atrogin-1 protein levels.

Results—TGF- β decreased muscle fiber size and dramatically reduced maximum isometric force production. TGF- β also induced scleraxis expression in muscle fibroblasts, and increased procollagen I α 2 and atrogin-1 levels in muscles.

Discussion—These results provide new insight into the effect of TGF- β on muscle contractility and the molecular mechanisms behind TGF- β -mediated muscle atrophy and fibrosis.

Keywords

Muscle contractility; Scleraxis; Atrogin-1; Type I collagen; Fibroblasts

Introduction

Transforming growth factor- β 1 (TGF- β) is a secreted cytokine that plays important roles in the biological activity of fibroblasts and in the regulation of extracellular matrix (ECM) production in many tissues. TGF- β was originally identified as a factor that promoted the proliferation of fibroblast cells and could transform normal cells into metastatic cancer cells¹. Subsequent studies have shown that TGF- β causes fibrosis and promotes inflammation in multiple tissues including skin, liver, kidney, lung, colon, heart and skeletal muscle²⁻⁷. Increased TGF- β signaling is also associated with several diseases of skeletal muscle, including many of the muscular dystrophies^{8,9}.

TGF- β is a 25 kDa protein composed of two disulfide linked subunits that is secreted into the extracellular matrix around cells in an inactive form bound to a latency associated peptide (LAP)^{9,3,10}. The LAP is degraded by proteases in the extracellular matrix, including matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), thrombospondin-1 (TSP-1), bone morphogenetic protein 1/Tolloid-like (BMP-1/TLD) metalloproteinases, as well as others^{11,3}. Many of these proteases become activated after skeletal muscle injury or remain persistently activated in several different types of skeletal muscle diseases¹². Once TGF- β is released from the LAP and becomes activated, it associates with TGF- β type II (TGF β RII) and type I (TGF β RI) serine/threonine kinase transmembrane receptors^{7,10}. The activated TGF β RI receptor activates two signaling pathways, the Smad2/3 pathway and the TAK1 MAPK pathway, which mediate many of the intracellular actions of TGF- β including synthesis of ECM proteins, cell motility and others^{7,10}.

In addition to causing severe fibrosis in many different tissues, the systemic administration of TGF- β leads to profound cachexia and muscle atrophy⁶. The ubiquitin-proteasome system is important in the regulation of the protein turnover rates and size of muscle fibers¹³. Atrogin-1 (MAFbx) is an E3 ubiquitin ligase expressed in skeletal muscle that directs the polyubiquitination of proteins to target them for proteolysis by the 26S proteasome^{14,15}. Atrogin-1 levels increase following immobilization or denervation, and mice that are deficient in atrogin-1 are resistant to denervation-induced skeletal muscle atrophy¹⁴. Insulin-like growth factor-1 (IGF-1) promotes muscle hypertrophy in part by downregulating atrogin-1 expression via the PI3K-Akt-Foxo3 pathway¹⁶. Treatment of myotubes with a cytokine that is related to TGF- β , myostatin, induced the atrophy of myotubes, and increased atrogin-1 expression and protein ubiquitination¹⁷. The molecular mechanisms behind muscle atrophy mediated by TGF- β , however, are not well understood.

Scleraxis (Scx) is a bHLH transcription factor that is expressed in fibroblasts in the connective tissue of limbs during development¹⁸. Scleraxis promotes fibroblast proliferation and type I collagen synthesis^{19,20}. Consistent with this, mice with a targeted inactivation of scleraxis fail to properly form limb tendons during embryonic development²¹. TGF- β appears to play an important role in scleraxis expression during development, as TGF β RII KO embryos have a marked reduction in scleraxis expression and a subsequent disruption in the formation of limb tendons²². While TGF- β appears to be important in the induction of scleraxis expression during development, the role that TGF- β plays in regulating scleraxis expression in fibroblasts of adult skeletal muscle is not known.

To gain a greater understanding of the role of TGF- β in the regulation of skeletal muscle atrophy and fibrosis, we determined the impact of recombinant TGF- β treatment on the contractile and morphological properties of skeletal muscles from the anterior compartment of the lower hindlimb of transgenic mice that express GFP under the control of 4kb of the scleraxis promoter. We also determined the effect of TGF- β treatment on the levels of atrogin-1, scleraxis and procollagen I protein content in muscles. We hypothesized that, compared with control muscles, muscles treated with TGF- β would have a reduction in maximum isometric force, an induction of muscle fiber atrophy, and an increase in atrogin-1, scleraxis and procollagen I α 2 protein levels.

Materials and Methods

Animals

All experiments were conducted with approval from the University of Michigan Committee on the Care and Use of Animals. Four month old male mice that express green fluorescent protein (GFP) under the control of 4kb of the scleraxis promoter (ScxGFP mice) were used

in this study¹⁸. The ScxGFP strain of mice was kindly provided by Dr. Ronen Schweitzer. Mice were housed under specific pathogen free conditions and provided food and water *ad libidum*.

TGF- β Treatment and Operative Procedure

Mice were anesthetized with isoflurane and the hindlimbs were shaved and cleaned. For each mouse, 100 μ L of a solution containing 2ng/mL of recombinant TGF- β (R&D Systems) in sterile phosphate buffered saline (PBS, Thermo Scientific) was carefully injected subcutaneously around the anterior compartment of the left lower hindlimb, and 100 μ L of sterile PBS (vehicle only) was injected subcutaneously around the anterior compartment of the right lower hindlimb. Mice were allowed to recover and returned to their cages. Five days after injections, the extensor digitorum longus (EDL) and tibialis anterior (TA) muscles were removed under isoflurane anesthesia and the mice were humanely euthanized. The EDL muscle was used for contractility and histology experiments, while the TA muscle was used for immunoblots.

Skeletal Muscle Contractility

The contractility of EDL muscles was measured *in vitro* as previously described²³. Briefly, EDL muscles were placed in Krebs's mammalian Ringer solution supplemented with 0.25 mM tubocurarine chloride and the proximal tendon was attached to a force transducer (Kulite Semiconductor) and the distal tendon was attached to a servomotor (Aurora Scientific). The solution was maintained at 25°C and was bubbled with 95% O₂ and 5% CO₂ to stabilize the pH at 7.4. An IBM PC running custom designed LabVIEW software (National Instruments) was used to control experiments and store data. EDL muscles were stimulated by square pulses delivered from two platinum electrodes connected to a high-power biphasic current stimulator (Aurora Scientific). The voltage of pulses was increased and muscle length was adjusted to the length (L₀) that resulted in maximum twitch force (P₁). The time to peak tension (TTPT) of twitches and half relaxation time (HRT) for twitches were also recorded. Following twitch force measurement, muscles were maintained at L₀ and subjected to 300ms pulse trains to generate an isometric contraction. Stimulus frequency was increased until maximum isometric force (P₀) was achieved, typically around 120 Hz. The maximum rate of force development during the development of an isometric contraction (maximum dP/dt) was also determined. After contractile properties were determined, muscles were subsequently removed from the bath, mass was measured, and muscles were quickly frozen in for histology in TissueTek (Triangle Biomedical Sciences). To determine specific P₀ (sP₀), P₀ was normalized by cross-sectional area (CSA) measured by histology. This approach was chosen instead of normalizing by physiological CSA (PSCA) because the amount of fibrosis in the TGF- β treated muscles likely increased the density of muscles beyond the standard density of healthy skeletal muscle, $1.056\text{g} \times \text{cm}^{-3}$ ²⁴.

Histology

Muscles were sectioned midbelly with a cryostat at a thickness of 10 μ m. Sections were permeabilized using a 0.2% Triton X-100 solution and blocked using a Mouse on Mouse Blocking Kit (Vector Labs). Satellite cells were identified using a primary antibody against c-met (Santa Cruz) and an AlexaFluor 546-conjugated secondary antibody (Invitrogen). A biotinylated primary antibody against collagen I (AbCam) and AlexaFluor 647 conjugated to streptavidin (Invitrogen) was used to identify extracellular matrix. Nuclei were identified using DAPI. Slides were mounted in Prolong Gold (Invitrogen) and were imaged using a Axioplan 2 microscope (Zeiss). Histomorphometry of digital images was performed using ImageJ software.

Immunoblots

TA muscles were homogenized in Laemmli's sample buffer with 1:20 β -mercaptoethanol and 1:20 protease inhibitor cocktail (Sigma) and subsequently placed in boiling water for 2 minutes. Protein concentration was determined using a Non-Interfering Protein Assay (G-Biosciences) and 15 μ g of protein was loaded into AnyKD mini-gels (BioRad) and subjected to electrophoretic separation. For atrogen-1, scleraxis and β -tubulin blots, proteins were transferred from gels onto PVDF membranes (Millipore), blocked with 2% goat serum, and incubated with antibodies against atrogen-1 (ECM Biosciences), scleraxis (AbCam) or β -tubulin (AbCam). Procollagen I blotting was performed by transferring proteins from gels onto nitrocellulose membranes (BioRad) which were subsequently placed in 95°C water for 5 minutes, blocked with 5% non-fat powdered milk and incubated with antibodies against procollagen I (Santa Cruz). Following primary antibody incubation, membranes were rinsed and incubated with HRP-conjugated secondary antibodies (Santa Cruz). Proteins were detected using SuperSignal West Dura enhanced chemiluminescent reagents (Pierce) and visualized using a digital chemiluminescent documentation system (Alpha Innotech).

Statistical Analyses

Results are presented as mean $\pm$ SE. KaleidaGraph 4.1 software (Synergy Software) was used to conduct statistical analyses. Differences between groups were tested using Student's t-test with $\alpha = 0.05$.

Results

The morphological and contractile properties of EDL muscles treated with vehicle ($-$ TGF- β) or with 200pg of recombinant TGF- β ($+$ TGF- β) are shown in Table 1. The treatment of muscles with TGF- β did not change muscle mass, but did result in a 21% decrease the CSA of whole EDL muscles and a 38% reduction in the CSA of individual EDL muscle fibers (Table 1). Consistent with an induction of muscle atrophy and accumulation of ECM, the contractile forces of TGF- β treated muscles were also reduced. Compared with control muscles, TGF- β treated muscles had a 75% reduction in P_t , a 66% reduction in sP_t , no change in TTPT and an 89% increase in HRT (Table 1). For isometric contractions, TGF- β treated muscle displayed a 72% decrease in P_o , a 61% reduction in sP_o and 73% reduction in maximum dP/dt (Table 1).

In control muscles from ScxGFP mice, scleraxis was expressed in fibroblasts in the perimysium as well as in the epimysium, and these scleraxis-expressing fibroblasts were often located adjacent to satellite cells (Figure 1A). TGF- β treatment resulted in the activation of these fibroblasts, an increase in the collagen I content of the muscle ECM and an atrophy of muscle fibers (Figure 1B). Compared with vehicle-treated muscles, treatment with TGF- β also increased the levels of scleraxis, procollagen I α 2 and atrogen-1 levels in muscles as measured by immunoblot (Figure 2). β -tubulin is used as a loading control to verify equal protein loading (Figure 2).

Discussion

The significance of this study lies in the new insights gained into the role of TGF- β in the induction of skeletal muscle atrophy and fibrosis. In addition, by measuring the contractile properties of muscles, we demonstrated for the first time that TGF- β causes a dramatic reduction in the force generating capacity of otherwise healthy muscle tissue. Previous studies of the effects of TGF- β in skeletal muscle have utilized direct injurious intramuscular injections of TGF- β or have correlated TGF- β levels with the severity of muscle disease or injury pathology. Our approach allowed us to specifically evaluate the effect of TGF- β in

intact whole muscle tissue without the confounding effects of direct muscle injury or disease.

Our results indicate that TGF- β can directly induce muscle fiber atrophy in the absence of physical injury to muscle and in a satellite cell-independent fashion. We observed a decrease in muscle fiber CSA in TGF- β treated muscles, and although no change in whole muscle mass was observed, any reduction in muscle mass due to individual fiber atrophy was likely offset by the accumulation of collagen in the muscle ECM. TGF- β plays an important role in the regulation of skeletal muscle satellite cell activity. TGF- β can cause satellite cell apoptosis and can potentially inhibit the proliferation and fusion of satellite cells, even in the presence of the mitogenic growth factors IGF-1 and FGF-2²⁵⁻²⁸. A cytokine related to TGF- β , myostatin, activates similar signaling pathways as TGF- β and also inhibits satellite cell proliferation and fusion^{29,30}. As satellite cells play an important role in the regeneration of muscle fibers following injury³¹, an inhibition of satellite cell activity during muscle regeneration could lead to muscle fiber atrophy. Our observations of individual fiber atrophy in muscles exposed to TGF- β in the absence of muscle injury support effects of TGF- β that are independent of its known effects on satellite cells.

The association demonstrated in the present study of TGF- β induced fiber atrophy with an upregulation of expression of the E3 ubiquitin ligase atrogin-1 is consistent with the findings of Sartori and colleagues³² who demonstrated that transfection of a constitutively active TGF β RI into the tibialis anterior muscles of mice resulted in muscle fiber atrophy and a Smad3-dependant activation of the atrogin-1 promoter. Additionally, in the model system *Caenorhabditis elegans*, expression of MFB-1, an atrogin-1 homologue, is regulated by the TGF- β homologue, DAF-7³³. While the regulation of satellite cell activity is an important factor in determining muscle fiber size, taken together these results suggest that TGF- β may directly induce muscle fiber atrophy, at least in part, by increasing the atrogin-1 protein levels within muscle fibers. Further studies that evaluate specific components of the TGF- β signal transduction pathway will provide additional insight into the molecular mechanisms of TGF- β -mediated skeletal muscle atrophy.

While much attention has focused on the role of satellite cells in the determination of muscle function, relatively little attention has been paid to the biology of muscle fibroblast cells. Li and colleagues⁴ performed a direct intramuscular injection of 5ng of recombinant TGF- β into the TA muscles of mice and observed a dramatic induction of fibrosis and muscle fiber atrophy. Using less than a twentieth of this dose delivered subcutaneously, we also observed a decrease in the size of muscle fibers and an increase in collagen I levels in muscle. Li⁴ also reported that when C₂C₁₂ myoblast cells that were modified to overexpress TGF- β were injected into immunodeficient mice, these transplanted myoblast cells displayed the ability to transdifferentiate into fibroblasts *in vivo*. In control muscles, we identified a population of fibroblast cells that express scleraxis. Interestingly, in many cases these fibroblasts were located adjacent to quiescent satellite cells. In response to TGF- β treatment, the number of fibroblasts did not appear to change, rather, the cells became enlarged, had an increase in scleraxis levels and a greater accumulation of collagen I in their surrounding ECM. These results support the notion that TGF- β signaling regulates the activity of fibroblast cells in skeletal muscle, and that scleraxis may be an important regulator of fibrosis in adult skeletal muscle tissue.

Following injury to skeletal muscles, there is an increase in the expression of TGF- β ^{34,35} and an activation of the TGF- β molecules that are present in the ECM around muscle fibers³⁶, although the role of TGF- β in the injury and recovery process is not clear. TGF- β also appears to play an important role in muscle wasting associated with congenital diseases such as Duchenne muscular dystrophy⁸. Suramin, a polysulfonated naphthylurea molecule,

improved the regeneration of skeletal muscles in mdx mice³⁷ and also improved the recovery of muscles following injury³⁸⁻⁴⁰. Suramin inhibits the binding of several growth factors to their receptors, including the proinflammatory cytokines TGF- β and myostatin, and the anti-inflammatory and protein synthesis cytokines FGF-1, FGF-2, IGF-1 and PDGF^{41,40}. While the non-specific inhibition of TGF- β using a compound like suramin offers some promise, the use of a more specific inhibitor of TGF- β may further promote muscle regeneration by blocking the cachectic effects of TGF- β signaling without reducing the activities of other anabolic growth factors. Identifying other cytokines that control the expression of atrogen-1 and scleraxis may also promote functional muscle regeneration and reduce the deposition of scar tissue.

Acknowledgments

The ScxGFP mice were a kind gift of Dr. Ronen Schweitzer. This work was supported by grants AR058920 and AR055624 from NIAMS.

References

1. Anzano MA, Roberts AB, Smith JM, Sporn MB, De Larco JE. Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors. *Proc Natl Acad Sci USA*. 1983; 80(20):6264–6268. [PubMed: 6604914]
2. Heldin C-H. Development and possible clinical use of antagonists for PDGF and TGF-beta. *Ups J Med Sci*. 2004; 109(3):165–178. [PubMed: 15508523]
3. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. *FASEB J*. 2004; 18(7):816–827. [PubMed: 15117886]
4. Li Y, Foster W, Deasy BM, Chan Y, Prisk V, Tang Y, Cummins J, Huard J. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. *Am J Pathol*. 2004; 164(3):1007–1019. [PubMed: 14982854]
5. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. *Proc Natl Acad Sci USA*. 1986; 83(12):4167–4171. [PubMed: 2424019]
6. Zugmaier G, Paik S, Wilding G, Knabbe C, Bano M, Lupu R, Deschauer B, Simpson S, Dickson RB, Lippman M. Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. *Cancer Res*. 1991; 51(13):3590–3594. [PubMed: 2054795]
7. Pohlers D, Brenmoehl J, Löffler I, Müller CK, Leipner C, Schultze-Mosgau S, Stallmach A, Kinne RW, Wolf G. TGF-beta and fibrosis in different organs - molecular pathway imprints. *Biochim Biophys Acta*. 2009; 1792(8):746–756. [PubMed: 19539753]
8. Chen Y-W, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, Hoffman EP. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. *Neurology*. 2005; 65(6):826–834. [PubMed: 16093456]
9. Kollias HD, McDermott JC. Transforming growth factor-beta and myostatin signaling in skeletal muscle. *J Appl Physiol*. 2008; 104(3):579–587. [PubMed: 18032576]
10. ten Dijke P, Hill CS. New insights into TGF-beta-Smad signalling. *Trends Biochem Sci*. 2004; 29(5):265–273. [PubMed: 15130563]
11. Hopkins DR, Keles S, Greenspan DS. The bone morphogenetic protein 1/Tolloid-like metalloproteinases. *Matrix Biol*. 2007; 26(7):508–523. [PubMed: 17560775]
12. Carmeli E, Moas M, Reznick AZ, Coleman R. Matrix metalloproteinases and skeletal muscle: a brief review. *Muscle Nerve*. 2004; 29(2):191–197. [PubMed: 14755482]
13. Jackman RW, Kandarian SC. The molecular basis of skeletal muscle atrophy. *Am J Physiol, Cell Physiol*. 2004; 287(4):C834–843. [PubMed: 15355854]

14. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ. Identification of ubiquitin ligases required for skeletal muscle atrophy. *Science*. 2001; 294(5547):1704–1708. [PubMed: 11679633]
15. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. *Proc Natl Acad Sci USA*. 2001; 98(25):14440–14445. [PubMed: 11717410]
16. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. *Cell*. 2004; 117(3):399–412. [PubMed: 15109499]
17. McFarlane C, Plummer E, Thomas M, Henneby A, Ashby M, Ling N, Smith H, Sharma M, Kambadur R. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. *J Cell Physiol*. 2006; 209(2):501–514. [PubMed: 16883577]
18. Pryce BA, Brent AE, Murchison ND, Tabin CJ, Schweitzer R. Generation of transgenic tendon reporters, ScxGFP and ScxAP, using regulatory elements of the scleraxis gene. *Dev Dyn*. 2007; 236(6):1677–1682. [PubMed: 17497702]
19. Edom-Vovard F, Duprez D. Signals regulating tendon formation during chick embryonic development. *Dev Dyn*. 2004; 229(3):449–457. [PubMed: 14991700]
20. Léjard, Brideau, Blais, Salingcarboriboon, Wagner, Roehrl, Noda, Duprez, Houillier, Rossert. Scleraxis and NFATc regulate the expression of the pro-alpha 1(I) collagen gene in tendon fibroblasts. *J Biol Chem*. 2007
21. Murchison, Price, Conner, Keene, Olson, Tabin, Schweitzer. Regulation of tendon differentiation by scleraxis distinguishes force-transmitting tendons from muscle-anchoring tendons. *Development*. 2007
22. Pryce BA, Watson SS, Murchison ND, Staverosky JA, Dünker N, Schweitzer R. Recruitment and maintenance of tendon progenitors by TGF{beta} signaling are essential for tendon formation. *Development*. 2009; 136(8):1351–1361. [PubMed: 19304887]
23. Mendias CL, Marcin JE, Calderon DR, Faulkner JA. Contractile properties of EDL and soleus muscles of myostatin-deficient mice. *J Appl Physiol*. 2006; 101(3):898–905. [PubMed: 16709649]
24. Faulkner J, Claflin D, McCully K, Jones D. Contractile properties of bundles of fiber segments from skeletal muscles. *AJP - Cell Physiology*. 1982; 243(1):C66.
25. Allen RE, Boxhorn LK. Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta. *J Cell Physiol*. 1987; 133(3):567–572. [PubMed: 3480289]
26. Allen RE, Boxhorn LK. Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor I, and fibroblast growth factor. *J Cell Physiol*. 1989; 138(2):311–315. [PubMed: 2918032]
27. Allen RE, Temm-Grove CJ, Sheehan SM, Rice G. Skeletal muscle satellite cell cultures. *Methods Cell Biol*. 1997; 52:155–176. [PubMed: 9379949]
28. Li X, McFarland DC, Velleman SG. Transforming growth factor-beta1-induced satellite cell apoptosis in chickens is associated with beta1 integrin-mediated focal adhesion kinase activation. *Poult Sci*. 2009; 88(8):1725–1734. [PubMed: 19590089]
29. Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, Kambadur R. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. *J Biol Chem*. 2002; 277(51):49831–49840. [PubMed: 12244043]
30. McCroskery S, Thomas M, Maxwell L, Sharma M, Kambadur R. Myostatin negatively regulates satellite cell activation and self-renewal. *J Cell Biol*. 2003; 162(6):1135–1147. [PubMed: 12963705]
31. Hawke TJ, Garry DJ. Myogenic satellite cells: physiology to molecular biology. *J Appl Physiol*. 2001; 91(2):534–551. [PubMed: 11457764]
32. Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R, Sandri M. Smad2 and 3 transcription factors control muscle mass in adulthood. *Am J Physiol, Cell Physiol*. 2009; 296(6):C1248–1257. [PubMed: 19357234]

33. Aoyama Y, Urushiyama S, Yamada M, Kato C, Ide H, Higuchi S, Akiyama T, Shibuya H. MFB-1, an F-box-type ubiquitin ligase, regulates TGF-beta signalling. *Genes Cells*. 2004; 9(11):1093–1101. [PubMed: 15507120]
34. Noirez P, Torres S, Cebrian J, Agbulut O, Peltzer J, Butler-Browne G, Daegelen D, Martelly I, Keller A, Ferry A. TGF-beta1 favors the development of fast type identity during soleus muscle regeneration. *J Muscle Res Cell Motil*. 2006; 27(1):1–8. [PubMed: 16362724]
35. Smith CA, Stauber F, Waters C, Alway SE, Stauber WT. Transforming growth factor-beta following skeletal muscle strain injury in rats. *J Appl Physiol*. 2007; 102(2):755–761. [PubMed: 17068209]
36. Philippou A, Maridaki M, Koutsilieris M. The role of urokinase-type plasminogen activator (uPA) and transforming growth factor beta 1 (TGFbeta1) in muscle regeneration. *In Vivo*. 2008; 22(6): 735–750. [PubMed: 19181000]
37. Taniguti AP, Pertille A, Matsumura CY, Santo Neto H, Marques MJ. Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-beta1 blocker. *Muscle Nerve*. 2011; 43(1):82–87. [PubMed: 21108244]
38. Chan Y-S, Li Y, Foster W, Fu FH, Huard J. The use of suramin, an antifibrotic agent, to improve muscle recovery after strain injury. *Am J Sports Med*. 2005; 33(1):43–51. [PubMed: 15610998]
39. Chan Y-S, Li Y, Foster W, Horaguchi T, Somogyi G, Fu FH, Huard J. Antifibrotic effects of suramin in injured skeletal muscle after laceration. *J Appl Physiol*. 2003; 95(2):771–780. [PubMed: 12730151]
40. Nozaki M, Li Y, Zhu J, Ambrosio F, Uehara K, Fu FH, Huard J. Improved muscle healing after contusion injury by the inhibitory effect of suramin on myostatin, a negative regulator of muscle growth. *Am J Sports Med*. 2008; 36(12):2354–2362. [PubMed: 18725651]
41. Middaugh CR, Mach H, Burke CJ, Volkin DB, Dabora JM, Tsai PK, Bruner MW, Ryan JA, Marfia KE. Nature of the interaction of growth factors with suramin. *Biochemistry*. 1992; 31(37): 9016–9024. [PubMed: 1390688]

Abbreviations

CSA	Cross sectional area
ECM	Extracellular matrix
EDL	Extensor digitorum longus
GFP	Green fluorescent protein
HRT	Half relaxation time
L₀	Optimum length
Maximum dP/dt	Maximum rate of force development
P₀	Maximum isometric force
PBS	Phosphate buffered saline
Scx	Scleraxis
sP₀	Specific maximum isometric force
TA	Tibialis anterior
TGF-β	Transforming growth factor-β
TTPT	Time to peak tension

Figure 1. Immunohistochemistry of EDL muscles treated with PBS (A) or TGF- β (B). Nuclei (DAPI), blue; Collagen I, red; satellite cells (c-met), orange; fibroblasts (ScxGFP), green. Scale bar = 5 μ m.

Figure 2.

Immunoblot of atrogin-1, scleraxis, procollagen Iα2 and β-tubulin from TA muscles of paired hindlimbs from four representative mice treated either with PBS (–TGF-β) or with TGF-β (+TGF-β). β-tubulin is used as a loading control.

Table 1

Morphological and contractile properties from vehicle treated ($-TGF-\beta$) and $TGF-\beta$ treated ($+TGF-\beta$) EDL muscles.

	$-TGF-\beta$	$+TGF-\beta$
Mass (mg)	10.0 $\pm$ 0.3	9.8 $\pm$ 0.6
Whole Muscle CSA (mm ²)	1.74 $\pm$ 0.14	1.38 $\pm$ 0.13*
Muscle Fiber CSA (μ m ²)	1156.9 $\pm$ 76.2	716.5 $\pm$ 42.5*
<i>Twitch</i>		
P _i (mN)	119.4 $\pm$ 5.4	29.3 $\pm$ 8.8*
sP _i (mN/mm ²)	71.5 $\pm$ 6.5	24.0 $\pm$ 7.2*
TTPT (ms)	17.3 $\pm$ 1.9	17.4 $\pm$ 1.6
HRT (ms)	16.3 $\pm$ 0.4	30.9 $\pm$ 2.8*
<i>Isometric</i>		
P _o (mN)	387.6 $\pm$ 4.2	110.0 $\pm$ 32.2*
sP _o (mN/mm ²)	231.8 $\pm$ 19.6	89.3 $\pm$ 26.6*
Maximum dP/dt (mN/ms)	14.1 $\pm$ 0.6	3.8 $\pm$ 1.2*

Mean $\pm$ SE, N = 7,

* indicates significantly different from $-TGF-\beta$ (p<0.05).